Boule Diagnostics AB (BOUL) - Net Assets
Based on the latest financial reports, Boule Diagnostics AB (BOUL) has net assets worth Skr161.50 Million SEK (≈ $17.38 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr465.40 Million ≈ $50.08 Million USD) and total liabilities (Skr303.90 Million ≈ $32.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Boule Diagnostics AB liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr161.50 Million |
| % of Total Assets | 34.7% |
| Annual Growth Rate | 3.82% |
| 5-Year Change | 0.11% |
| 10-Year Change | 43.01% |
| Growth Volatility | 24.7 |
Boule Diagnostics AB - Net Assets Trend (2005–2024)
This chart illustrates how Boule Diagnostics AB's net assets have evolved over time, based on quarterly financial data. Also explore Boule Diagnostics AB asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Boule Diagnostics AB (2005–2024)
The table below shows the annual net assets of Boule Diagnostics AB from 2005 to 2024. For live valuation and market cap data, see how much is Boule Diagnostics AB worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr269.60 Million ≈ $29.01 Million |
-43.25% |
| 2023-12-31 | Skr475.10 Million ≈ $51.13 Million |
+2.72% |
| 2022-12-31 | Skr462.50 Million ≈ $49.77 Million |
+56.39% |
| 2021-12-31 | Skr295.74 Million ≈ $31.83 Million |
+9.81% |
| 2020-12-31 | Skr269.30 Million ≈ $28.98 Million |
-19.10% |
| 2019-12-31 | Skr332.87 Million ≈ $35.82 Million |
+10.64% |
| 2018-12-31 | Skr300.86 Million ≈ $32.38 Million |
+14.93% |
| 2017-12-31 | Skr261.77 Million ≈ $28.17 Million |
+13.93% |
| 2016-12-31 | Skr229.76 Million ≈ $24.73 Million |
+21.88% |
| 2015-12-31 | Skr188.51 Million ≈ $20.29 Million |
+10.90% |
| 2014-12-31 | Skr169.99 Million ≈ $18.29 Million |
+33.34% |
| 2013-12-31 | Skr127.49 Million ≈ $13.72 Million |
-36.16% |
| 2012-12-31 | Skr199.69 Million ≈ $21.49 Million |
+3.55% |
| 2011-12-31 | Skr192.86 Million ≈ $20.75 Million |
+47.71% |
| 2010-12-31 | Skr130.56 Million ≈ $14.05 Million |
+29.41% |
| 2009-12-31 | Skr100.89 Million ≈ $10.86 Million |
-12.43% |
| 2008-12-31 | Skr115.22 Million ≈ $12.40 Million |
-4.24% |
| 2007-12-31 | Skr120.32 Million ≈ $12.95 Million |
+1.05% |
| 2006-12-31 | Skr119.08 Million ≈ $12.81 Million |
-10.03% |
| 2005-12-31 | Skr132.36 Million ≈ $14.24 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Boule Diagnostics AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2414.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr9.70 Million | 3.60% |
| Other Comprehensive Income | Skr48.50 Million | 17.99% |
| Other Components | Skr336.20 Million | 124.70% |
| Total Equity | Skr269.60 Million | 100.00% |
Boule Diagnostics AB Competitors by Market Cap
The table below lists competitors of Boule Diagnostics AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Laon People Inc.
KQ:300120
|
$14.38 Million |
|
Pelikan International Corp
KLSE:5231
|
$14.39 Million |
|
Perfect Moment Ltd.
NASDAQ:PMNT
|
$14.39 Million |
|
Mlk Foods Public Company Ltd
WAR:MLK
|
$14.40 Million |
|
Petrolympic Ltd
V:PCQ
|
$14.37 Million |
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
$14.37 Million |
|
The Western India Plywoods Limited
NSE:WIPL
|
$14.36 Million |
|
Anugerah Kagum Karya Utama Tbk PT
JK:AKKU
|
$14.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Boule Diagnostics AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 475,096,000 to 269,600,000, a change of -205,496,000 (-43.3%).
- Net loss of 223,300,000 reduced equity.
- Other comprehensive income increased equity by 17,850,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-223.30 Million | -82.83% |
| Other Comprehensive Income | Skr17.85 Million | +6.62% |
| Other Changes | Skr-46.00K | -0.02% |
| Total Change | Skr- | -43.25% |
Book Value vs Market Value Analysis
This analysis compares Boule Diagnostics AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr5.89 | Skr3.44 | x |
| 2009-12-31 | Skr5.16 | Skr3.44 | x |
| 2010-12-31 | Skr6.67 | Skr3.44 | x |
| 2011-12-31 | Skr8.40 | Skr3.44 | x |
| 2012-12-31 | Skr7.51 | Skr3.44 | x |
| 2013-12-31 | Skr4.79 | Skr3.44 | x |
| 2014-12-31 | Skr6.39 | Skr3.44 | x |
| 2015-12-31 | Skr7.02 | Skr3.44 | x |
| 2016-12-31 | Skr8.42 | Skr3.44 | x |
| 2017-12-31 | Skr9.55 | Skr3.44 | x |
| 2018-12-31 | Skr10.97 | Skr3.44 | x |
| 2019-12-31 | Skr12.14 | Skr3.44 | x |
| 2020-12-31 | Skr9.82 | Skr3.44 | x |
| 2021-12-31 | Skr10.50 | Skr3.44 | x |
| 2022-12-31 | Skr16.24 | Skr3.44 | x |
| 2023-12-31 | Skr12.16 | Skr3.44 | x |
| 2024-12-31 | Skr6.94 | Skr3.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Boule Diagnostics AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -82.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -39.97%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 2.19x
- Recent ROE (-82.83%) is below the historical average (-2.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -4.82% | -3.29% | 1.00x | 1.46x | Skr-17.07 Million |
| 2009 | -10.45% | -6.01% | 1.17x | 1.48x | Skr-20.64 Million |
| 2010 | 14.47% | 8.23% | 1.11x | 1.58x | Skr5.83 Million |
| 2011 | 6.07% | 4.76% | 0.91x | 1.41x | Skr-7.57 Million |
| 2012 | 5.49% | 3.98% | 1.00x | 1.38x | Skr-9.01 Million |
| 2013 | -55.00% | -25.33% | 1.25x | 1.73x | Skr-82.87 Million |
| 2014 | 17.80% | 9.87% | 1.10x | 1.65x | Skr13.27 Million |
| 2015 | 8.14% | 4.63% | 1.05x | 1.67x | Skr-3.50 Million |
| 2016 | 15.68% | 8.99% | 1.10x | 1.59x | Skr13.06 Million |
| 2017 | 14.23% | 8.70% | 1.03x | 1.59x | Skr11.06 Million |
| 2018 | 13.64% | 9.67% | 0.85x | 1.66x | Skr10.95 Million |
| 2019 | 11.28% | 7.53% | 0.85x | 1.76x | Skr4.26 Million |
| 2020 | -17.81% | -11.98% | 0.83x | 1.78x | Skr-74.90 Million |
| 2021 | 7.87% | 5.02% | 0.81x | 1.93x | Skr-6.30 Million |
| 2022 | 2.75% | 2.32% | 0.72x | 1.64x | Skr-33.52 Million |
| 2023 | 5.26% | 4.37% | 0.76x | 1.59x | Skr-22.53 Million |
| 2024 | -82.83% | -39.97% | 0.95x | 2.19x | Skr-250.26 Million |
Industry Comparison
This section compares Boule Diagnostics AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $157,771,031
- Average return on equity (ROE) among peers: -31.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Boule Diagnostics AB (BOUL) | Skr161.50 Million | -4.82% | 1.88x | $14.38 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Boule Diagnostics AB
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more